Actinium Pharmaceuticals Inc.
- Actinium Pharmaceuticals Inc. (NYSE:ATNM) is a clinical-stage biopharmaceutical company focused on developing and potentially commercializing targeted therapies for improved myeloablation (the decrease in bone marrow activity) and conditioning of the bone marrow prior to a bone marrow transplant and for the targeting and killing of cancer cells.
About the Leading Product, Iomab-B
- Iomab-B was created with the goal of improving bone marrow transplant (BMT) access and outcomes for patients with blood cancers such as leukemia, lymphoma or multiple myeloma.
- Iomab-B is intended to prepare and condition patients for a BMT which is often considered the only potential cure for patients with certain blood cancers.
- The drug carries iodine-131 directly to the bone marrow in a targeted manner with the intent for patients to avoid the side effects of radiation while effectively killing the patient’s cancer and marrow cells.
- Stage II clinical trials were a major success, as Iomab-B produced complete remissions in 100% of the 68 patients with advanced AML or high-risk myelodysplastic syndrome age 50 and older. All patients achieved full donor chimerism by day 28 post-transplant.
- Currently showing promise during stage III clinical trials, and approval is likely due to the lack of viable alternatives.
- Upon successful completion of the Phase 3 clinical trial for Iomab-B, Actinium intends to submit for marketing approval in the U.S. and European Union.
- Iomab-B will be marketed to patients with relapsed or refractory acute myeloid leukemia who are age 55 and above.
- According to the Journal of Medical Economics, the current cost for autologous and allogeneic BMTs ranges between $390,000 and $745,000. Actinium believes they can cut theses costs by reducing complications from BMT’s and diminishing inhouse days required for patients.
- Approximately 22,000 patients received an autologous or allogeneic BMT’s in the United States in 2015.
- This year, approximately 172,000 patients will be diagnosed with leukemia, lymphoma or multiple myeloma and that approximately 1.2 million patients are living with, or are in remission from these diseases.
- Actinium believes the aggregate worldwide market potential for the treatment of AML, MDS, ALL, Hodgkin’s Lymphoma, NHL and multiple myeloma is approximately $6.6 billion.
- Actinium shares have shown a drastic decrease in value over the past 5 years:
- The stock’s value peaked in March, 2014 at $12.40 and has trended downward to its current price of $0.38.
- The reduction in share price can be explained primarily by the longer than projected site activation times, education and coordination for Iomab-B.
- Actinium is targeting the second half of 2019 for Iomab-B’s Biologics License Application to the FDA, which, if approved, would allow Actinium to commercialize their drug.
- The potential approval would allow Actinium to infiltrate an emerging market and could reap tremendous financial gain for early investors.